Quick answer: The four most validated longevity interventions — in order of evidence strength — are: resistance training and aerobic exercise (the only interventions with consistent all-cause mortality reduction in every meta-analysis), caloric restriction and time-restricted eating (which activate the longevity pathways mTOR inhibition and AMPK/autophagy), optimal sleep (7–9 hours, with single nights of 4–5 hours showing 3x cancer, infection, and cardiovascular risk equivalence), and maintaining insulin sensitivity with fasting insulin below 5 μIU/mL (which determines IGF-1 signaling and cancer proliferation risk). The evidence-based supplement stack: NMN or NR for NAD+ restoration, rapamycin (off-label, prescription required), and the “Longevity 5” — metformin, resveratrol/pterostilbene, spermidine, fisetin, and quercetin.
The Biology of Aging: Why We Age and What Controls the Rate
Aging is not random deterioration — it is driven by conserved biological pathways that are increasingly understood and modifiable. The Hallmarks of Aging framework (Lopez-Otin et al., updated 2023) identifies 12 primary mechanisms: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis (protein quality control), disabled macroautophagy, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation (inflammaging), and dysbiosis. These hallmarks are interrelated — mitochondrial dysfunction produces reactive oxygen species that drive genomic instability and inflammation; senescent cells secrete inflammatory cytokines that damage neighboring cells; dysregulated mTOR signaling suppresses autophagy that would otherwise clear damaged proteins and organelles.
The critical insight from longevity research is that the rate of progression through these hallmarks is controllable. The fastest-aging systems are those with chronic energy excess (activated mTOR, suppressed AMPK), chronic inflammation (IL-6, CRP, TNF-α driven by visceral fat, gut dysbiosis, and sleep deprivation), and accumulated cellular senescence (senescent cells that persist rather than being cleared by apoptosis or immune surveillance). The interventions below target these pathways at a mechanistic level — they are not anti-aging marketing claims but interventions with documented effects on measurable aging biomarkers.
Measuring Your Biological Age
Chronological age and biological age diverge significantly between individuals. The most validated biological aging clocks include: the Horvath methylation clock (epigenetic age measured from DNA methylation patterns — the most widely validated, correlated with disease risk and all-cause mortality independently of chronological age), the GrimAge clock (a methylation-based predictor specifically optimized for mortality prediction — outperforms Horvath for disease risk stratification), telomere length (measured via qPCR or telomere FISH — shorter telomeres associate with disease risk and mortality, though with high individual variation), and phenotypic aging scores from standard labs (the PhenoAge algorithm uses 9 standard laboratory values including albumin, creatinine, CRP, lymphocytes, RBC volume, RBC distribution width, alkaline phosphatase, WBC, and glucose to calculate biological age).
Practical testing approach: the Levine PhenoAge score can be calculated from routine labs (available via tools at phenoage.com), providing a validated biological age estimate without specialized testing. For more comprehensive biological age assessment, epigenetic clocks are available through consumer services (TruAge, Elysium Index). Tracking these biomarkers over time — rather than a single measurement — reveals whether interventions are moving biological age in the right direction.
The Four Core Longevity Pillars
Pillar 1: Exercise — The Most Validated Longevity Intervention
Every meta-analysis of exercise and mortality shows consistent dose-dependent reduction in all-cause mortality — the effect size is larger than any medication or supplement. The specific prescriptions with the strongest longevity evidence: Zone 2 aerobic training (150–300 minutes per week at 60–70% max heart rate) maximizes mitochondrial biogenesis, AMPK activation, and visceral fat reduction. VO2max is the single strongest individual predictor of all-cause mortality identified in large cohort studies — each 1-MET improvement (approximately 3.5 mL/kg/min VO2max) corresponds to a 13% reduction in all-cause mortality. Resistance training (2–3 sessions/week) reduces all-cause mortality by 15–20% independently of aerobic exercise and prevents the sarcopenia and frailty that dramatically accelerate functional decline after age 60. High-intensity interval training (2x/week) specifically improves VO2max more efficiently than steady-state exercise and has independent evidence for cellular rejuvenation — a Mayo Clinic study found HIIT reverses age-related cellular decline in mitochondrial function in older adults more effectively than resistance training or combined moderate exercise.
Pillar 2: Caloric Restriction, TRE, and mTOR/AMPK Modulation
Caloric restriction (20–40% below ad libitum intake) extends lifespan in every organism tested — from yeast to worms to flies to rodents — and is the most replicated longevity intervention in biology. In humans, the CALERIE-2 RCT found that 25% caloric restriction for 2 years reduced multiple aging biomarkers including metabolic rate decline, inflammatory markers, and cardiometabolic risk factors. The mechanism is primarily inhibition of mTOR complex 1 (mTORC1) — the cellular nutrient sensor that, when chronically activated by amino acids and insulin, drives cellular growth at the expense of repair and maintenance. Reduced mTOR increases autophagy (clearance of damaged organelles and proteins), reduces senescent cell accumulation, and extends replicative lifespan. The practical challenge — sustained 25% caloric restriction is extremely difficult to maintain — has driven research into mTOR inhibition through dietary timing rather than restriction.
Time-restricted eating (TRE) and intermittent fasting recapitulate the mTOR inhibition and AMPK activation of caloric restriction without requiring chronic caloric reduction. During the fasting window, declining insulin and amino acids reduce mTORC1 activity, allowing the autophagy that is chronically suppressed by continuous eating. The 16–18 hour fasting window that initiates measurable autophagy is achievable for most people without significant caloric restriction — simply compressing eating into a 6–8 hour window produces the longevity-pathway activation that continuous eating suppresses. Fasting-mimicking diets (Prolon protocol: 5 consecutive days of 700–1,100 kcal/day, 3–4 times per year) produce even greater longevity biomarker improvements than daily TRE in clinical trials, including reductions in biological age clock measurements.
Pillar 3: Sleep — Non-Negotiable for Longevity
Sleep is the primary period of cellular repair and waste clearance. During slow-wave sleep, the glymphatic system removes amyloid beta and tau — the proteins that accumulate in Alzheimer’s disease — at rates 10x higher than during wakefulness. A single night of 4-hour sleep increases amyloid beta burden by 5% in PET studies. Chronic sleep restriction (6 hours/night) over 1 week produces performance deficits equivalent to 24 hours of total sleep deprivation while subjects report feeling “fine” — making chronic short sleep a particularly insidious risk. The U-shaped mortality curve for sleep duration (both short and long sleep associated with higher mortality) is driven by different mechanisms: short sleep increases inflammation, insulin resistance, and amyloid accumulation; long sleep is typically a marker of underlying disease rather than a cause of mortality. The optimal range for longevity is 7–9 hours with consistent sleep architecture.
Pillar 4: Metabolic Health — Insulin, IGF-1, and Cancer Risk
Hyperinsulinemia and elevated IGF-1 are among the strongest individual biomarkers for cancer risk — insulin and IGF-1 are growth factors that drive cellular proliferation via the PI3K/AKT/mTOR pathway. People with type 2 diabetes have 2x the all-cause cancer mortality, primarily driven by insulin’s pro-proliferative effects rather than glucose toxicity per se. Maintaining fasting insulin below 5 μIU/mL and HOMA-IR below 1.0 represents the metabolic target for longevity — these levels are associated with low mTOR activity, low inflammation, and optimal insulin receptor sensitivity. The PREDIMED study found that people with the highest insulin sensitivity (proxied by low triglyceride/HDL ratio) had 40% lower cardiovascular mortality than those with the lowest insulin sensitivity, independent of conventional risk factors.
Longevity Supplements: What the Evidence Actually Shows
NMN and NR: NAD+ Restoration
NAD+ declines 50% between age 20 and 60, impairing sirtuin activity, DNA repair capacity, and mitochondrial function. NMN (250–500 mg/day) and NR (300–600 mg/day) raise NAD+ measurably in human trials. The Washington University trial of NMN in older women found 38% NAD+ increase at 250 mg/day with significant improvements in muscle insulin sensitivity. NAD+ is required for PARP1 (DNA damage repair) and the sirtuins (SIRT1–7, which regulate gene expression, mitochondrial biogenesis, and cellular stress responses). Combining CD38 inhibitors (apigenin 50 mg/day, quercetin 500 mg/day) with NMN/NR is increasingly practiced — CD38 is an NADase that becomes increasingly active with age and inflammation, consuming NAD+ faster than precursors can restore it.
Rapamycin: The Only mTOR Inhibitor with Longevity Evidence
Rapamycin (an mTORC1 inhibitor) is the only compound that extends lifespan in multiple mammalian model organisms, including mice at late middle age. Interventional Testing Program (ITP) data shows 23% lifespan extension in male mice and 26% in females with rapamycin initiated at age 20 months (equivalent to age 60 in humans). Human use is increasingly practiced in longevity medicine as off-label intermittent dosing (typically 3–6 mg once weekly to avoid the continuous-use immunosuppression that occurs at transplant doses). Rapamycin requires a prescription and physician supervision — potential risks include glucose impairment, lipid changes, and infection susceptibility. This is not a self-treatment recommendation but a description of where the evidence stands for the most mechanistically compelling pharmacological longevity intervention currently available.
Senolytics: Clearing Zombie Cells
Senescent cells — cells that have permanently exited the cell cycle and resist apoptosis — accumulate with age and secrete the senescence-associated secretory phenotype (SASP): pro-inflammatory cytokines, proteases, and growth factors that damage neighboring cells and drive systemic inflammaging. Senolytics are compounds that selectively kill senescent cells. The most studied combination is dasatinib (5 mg, a tyrosine kinase inhibitor) plus quercetin (1,000 mg), taken intermittently (2–3 consecutive days per month — not daily). This combination is being tested in clinical trials for Alzheimer’s disease, idiopathic pulmonary fibrosis, and frailty. Fisetin (a flavonoid found in strawberries and apples) is the senolytic with the most straightforward supplement access — demonstrated 25–30% senescent cell clearance in mouse aging models at 100 mg/kg doses, with human trials ongoing. Spermidine (3–6 mg/day from fermented foods or supplements) is a potent autophagy inducer that reduces senescent cell accumulation and has observational data showing reduced all-cause mortality at higher dietary intake levels.
The Evidence-Based Longevity Stack
The practical supplement stack with the strongest evidence-to-risk profile for healthy aging: NMN 250–500 mg/day or NR 300–600 mg/day (NAD+ restoration), resveratrol 500 mg/day or pterostilbene 50–100 mg/day (SIRT1 activation, more bioavailable analog), spermidine 3–6 mg/day (autophagy induction), quercetin 500 mg/day (CD38 inhibition, senolytic at higher intermittent doses), fisetin 100 mg/day (senolytic, autophagy), vitamin D3 to 50–70 ng/mL (multiple longevity pathways including immune regulation, telomere maintenance, and cancer suppression), and omega-3 EPA+DHA 2–3 g/day (reduces inflammaging, triglycerides, and cardiovascular mortality). Berberine 500–1,000 mg/day can be substituted for or combined with metformin for AMPK activation and mTOR modulation.
The Longevity Labs Panel: What to Test
A comprehensive longevity biomarker panel: fasting insulin and HOMA-IR (metabolic aging), hs-CRP and fibrinogen (inflammaging), HbA1c, lipid panel with LDL particle size (ApoB), 25-hydroxyvitamin D, TSH with free T3 and T4 (thyroid — low T3 is independently associated with mortality), DHEA-S (adrenal reserve and anabolic/catabolic balance), testosterone (total and free — low testosterone in both men and women is independently associated with mortality), IGF-1 (growth hormone axis — modestly elevated IGF-1 with good insulin sensitivity is optimal; very high IGF-1 with hyperinsulinemia is pro-aging), homocysteine (B vitamin status and methylation capacity; elevated homocysteine drives cardiovascular aging and cognitive decline independently), and ferritin (iron overload accelerates aging via oxidative stress — optimal ferritin is 50–100 ng/mL, not just “in range”).
Longevity is not a single supplement or intervention — it is the compounding effect of consistently optimizing the biological systems that control the rate of aging. The foundation is non-negotiable: exercise (Zone 2 + resistance + HIIT), metabolic health (fasting insulin below 5), sleep optimization, and inflammation reduction. The pharmacological and supplemental tools accelerate the biological age trajectory when built on this foundation. Call our office at (810) 206-1402 to discuss a comprehensive longevity assessment and personalized protocol.
Frequently Asked Questions
What is the most effective longevity intervention?
Exercise — specifically the combination of Zone 2 aerobic training and resistance training — has the largest and most consistent effect on all-cause mortality in human data. Every additional MET of VO2max corresponds to approximately 13% reduction in all-cause mortality. Resistance training independently reduces all-cause mortality by 15-20%. No supplement or pharmacological intervention has comparable human evidence for mortality reduction. After exercise, maintaining insulin sensitivity (fasting insulin below 5 μIU/mL), optimizing sleep (7-9 hours), and chronic inflammation control have the next strongest evidence base.
Do NMN and NR supplements actually work?
Human clinical trials confirm that NMN and NR measurably raise NAD+ levels. The Washington University trial found 250 mg/day NMN raised NAD+ 38% in older women and improved muscle insulin sensitivity. NAD+ is required for SIRT1/3 activation, PARP1 DNA repair, and mitochondrial energy production — all of which decline with age. Whether this translates to longevity in humans is still under investigation (no long-term human mortality data exists yet), but the mechanistic rationale is strong and the safety profile is favorable. The effective dose range is NMN 250-500 mg/day or NR 300-600 mg/day, and combining with CD38 inhibitors (quercetin, apigenin) enhances efficacy by reducing NAD+ degradation.
What supplements should I take for longevity?
The evidence-based longevity stack with the best risk-benefit profile: NMN or NR (NAD+ restoration), vitamin D3 to 50-70 ng/mL serum level, omega-3 EPA+DHA 2-3 g/day (reduces cardiovascular mortality and inflammaging), spermidine 3-6 mg/day (autophagy induction), quercetin 500 mg/day (CD38 inhibition and senolytic activity), fisetin 100 mg/day (senolytic and autophagy), and magnesium glycinate 300-400 mg/day (cofactor for DNA repair enzymes, sleep quality, and insulin signaling). These address the core aging hallmarks: NAD+ decline, cellular senescence, autophagy suppression, inflammation, and mitochondrial dysfunction.
What is the most important thing you can do to live longer?
Exercise — specifically improving VO2max — is the single most evidence-based longevity intervention. Peter Attia’s analysis of NHANES data found that the difference in all-cause mortality between the bottom fitness quartile and the next quartile up is greater than the difference between any two adjacent groups higher in the fitness distribution. Moving from sedentary to minimally fit reduces mortality risk more than quitting smoking in most analyses. After exercise, the second priority is maintaining metabolic health (keeping fasting insulin below 5 μIU/mL and avoiding the insulin resistance-cancer-cardiovascular disease pathway), and third is sleep optimization for glymphatic clearance and cellular repair.